secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0001193125-25-286158
Event type: debt
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent completes $230M 1.625% convertible senior notes offering due 2031
------------------------------------------------------------------------

- Aggregate principal $230M including full exercise of $30M over-allotment option by underwriters.
- Notes bear 1.625% interest payable semiannually on May 15 and Nov 15, starting May 15, 2026; mature Nov 15, 2031.
- Initial conversion rate 22.2469 shares per $1,000 principal (conversion price ~$44.95); settlement in cash, stock, or combo at company's election.
- Notes are senior unsecured obligations; redeemable at company's option after Nov 20, 2029 subject to stock price conditions.
- Noteholders may require repurchase upon a Fundamental Change (e.g., business combination, delisting) at principal plus accrued interest.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000119312525286158/0001193125-25-286158-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000119312525286158/d888858d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-286158

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer